Search results
Results from the WOW.Com Content Network
Positron emission tomography (PET) [1] is a functional imaging technique that uses radioactive substances known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
According to Blue Cross, pet owners can expect for their pet to live about 12 months with current treatments. If the owner opts for palliative care instead of treatment, the dog will live about 3 months, although if the tumor is partially removed this can be extended. The survival time may be longer in large dogs, and the cure rate is 20%.
Positron emission tomography–computed tomography (better known as PET-CT or PET/CT) is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography (PET) scanner and an x-ray computed tomography (CT) scanner, to acquire sequential images from both devices in the same session, which are combined into a single superposed (co-registered) image.
One clear advantage of PET-MR compared to PET-CT is the lower total ionising radiation dose obtained. For body PET-CT applications, the CT part of the examination constitutes approximately 60-80% of the radiation dose, with the remaining radiation dose originating from the PET radiopharmaceutical. [30]
The AOL.com video experience serves up the best video content from AOL and around the web, curating informative and entertaining snackable videos.
Radiotherapy can be integrated with imaging techniques to guide treatment planning, monitor radiation dose distribution, and assess treatment response. Molecular imaging methods, such as PET and SPECT , can be employed to visualize and quantify tumor characteristics, such as hypoxia or receptor expression , aiding in personalized radiation dose ...
Radionuclide therapy can be used to treat conditions such as hyperthyroidism, thyroid cancer, skin cancer and blood disorders. In nuclear medicine therapy, the radiation treatment dose is administered internally (e.g. intravenous or oral routes) or externally direct above the area to treat in form of a compound (e.g. in case of skin cancer).
There is a risk of radiation exposure to other individuals (women/children/fetus), anaphylaxis, neutropenia (low neutrophils), and thrombocytopenia (low platelet). Zevalin, another radioligand therapy that targets non-Hodgkin lymphoma CD20 ligand but using Yttrium-90 as the radioisotope, was FDA approved in 2002.